CN102164884A - 羟基丁酸酯及其医学用途 - Google Patents
羟基丁酸酯及其医学用途 Download PDFInfo
- Publication number
- CN102164884A CN102164884A CN2009801367231A CN200980136723A CN102164884A CN 102164884 A CN102164884 A CN 102164884A CN 2009801367231 A CN2009801367231 A CN 2009801367231A CN 200980136723 A CN200980136723 A CN 200980136723A CN 102164884 A CN102164884 A CN 102164884A
- Authority
- CN
- China
- Prior art keywords
- compound
- treatment
- experimenter
- illness
- rat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
- C07C69/675—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Food Science & Technology (AREA)
- Child & Adolescent Psychology (AREA)
- Toxicology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Hospice & Palliative Care (AREA)
- Polymers & Plastics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
酮膳食(KD) | 普通人膳食(NHD) | 碳水化合物膳食(CHOD) | |
碳水化合物 | 38.5 | 38.6 | 70.2 |
蛋白质 | 26.9 | 27.0 | 26.2 |
脂肪 | 3.7 | 34.3 | 3.7 |
酮单酯 | 31 | 0 | 0 |
总计 | 100 | 100 | 100 |
酮膳食 | 普通人膳食(NHD) | 碳水化合物膳食(CHOD) | |
啮鼠动物食物 | 25.7 | 25.7 | 25.7 |
无糖果冻 | 13.4 | 13.4 | 13.4 |
水 | 49.6 | 55.1 | 46.3 |
棕榈油 | 0 | 5.8 | 0 |
玉米粉 | 0 | 0 | 14.5 |
酮单酯 | 11.4 | 0 | 0 |
总计 | 100 | 100 | 100 |
成分 | 淀粉 | 脂肪 | 酮酯 |
食物 | 25.7 | 25.7 | 25.7 |
无糖果冻 | 13.4 | 13.4 | 13.4 |
水 | 46.3 | 55.1 | 49.6 |
棕榈油 | 0 | 5.8 | 0 |
玉米淀粉 | 14.5 | 0 | 0 |
酮酯 | 0 | 0 | 11.4 |
总计 | 100 | 100 | 100 |
成分 | 淀粉 | 脂肪 | 酮酯 |
碳水化合物 | 70.2 | 38.6 | 38.5 |
蛋白质 | 26.2 | 27 | 26.9 |
脂肪 | 3.7 | 34.3 | 3.7 |
酮酯 | 0 | 0 | 31 |
总计 | 100 | 100 | 100 |
淀粉 | 脂肪 | 酮酯 | |
柠檬酸盐 | 0.199±0.006 | 0.205±0.005 | 0.222±0.010 |
异柠檬酸盐 | 0.0080±0.0006 | 0.0086±0.0004 | 0.0093±0.008 |
α-酮戊二酸盐 | 0.128±0.007 | 0.138±0.008 | 0.140±0.008 |
琥珀酰CoA(μM) | 0.831±0.075 | 0.777±0.158 | 0.910±0.207 |
琥珀酸盐 | 0.0800±0.0022 | 0.0822±0.0034 | 0.0864±0.0033 |
延胡索酸盐 | 0.0728±0.0042 | 0.0801±0.0055 | 0.0745±0.0058 |
L-苹果酸盐 | 0.179±0.011 | 0.192±0.012 | 0.181±0.013 |
草酰乙酸钙 | 0.0026±0.0003 | 0.0021±0.0001 | 0.0026±0.0004 |
乙酰基CoA(μM) | 7.87±1.32 | 8.20±1.02 | 6.43±0.53 |
丙二酰CoA(μM) | 0.954±0.061 | 1.02±0.14 | 1.26±0.13a |
Claims (25)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9075108P | 2008-08-21 | 2008-08-21 | |
US61/090,751 | 2008-08-21 | ||
PCT/US2009/040766 WO2010021766A1 (en) | 2008-08-21 | 2009-04-16 | Hydroxybutyrate ester and medical use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102164884A true CN102164884A (zh) | 2011-08-24 |
CN102164884B CN102164884B (zh) | 2015-03-11 |
Family
ID=40885956
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200980136723.1A Active CN102164884B (zh) | 2008-08-21 | 2009-04-16 | 羟基丁酸酯及其医学用途 |
Country Status (11)
Country | Link |
---|---|
EP (3) | EP4011374A1 (zh) |
JP (2) | JP5773870B2 (zh) |
CN (1) | CN102164884B (zh) |
AU (1) | AU2009283171B2 (zh) |
CA (1) | CA2734720C (zh) |
DK (2) | DK2328858T3 (zh) |
ES (2) | ES2907630T3 (zh) |
HK (1) | HK1159604A1 (zh) |
NO (1) | NO2328858T3 (zh) |
PL (2) | PL3296284T3 (zh) |
WO (1) | WO2010021766A1 (zh) |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103860533A (zh) * | 2014-02-12 | 2014-06-18 | 新乡医学院 | β羟基丁酸在治疗帕金森病中的应用 |
CN105246870A (zh) * | 2013-03-14 | 2016-01-13 | 伊希斯创新有限公司 | (r)-3-羟基丁酸(r)-3-羟基丁酯的制备方法 |
CN106456686A (zh) * | 2014-03-19 | 2017-02-22 | 斯坦陵布什大学 | 用于治疗或增强肌肉组织的方法 |
CN109700021A (zh) * | 2019-03-04 | 2019-05-03 | 清华大学 | 3-羟基丁酸及其衍生物在制备预防和治疗肥胖及肥胖相关疾病的产品中的应用 |
CN110248652A (zh) * | 2016-12-23 | 2019-09-17 | 鲁汶大学 | 3-羟基丁酸单独或组合用于治疗重症监护治疗 |
CN111050764A (zh) * | 2017-07-21 | 2020-04-21 | 巴克老年研究所 | β-羟基丁酸酯和丁二醇的S对映异构体及其使用方法 |
CN111132674A (zh) * | 2017-09-27 | 2020-05-08 | 泰德尔塔有限公司 | 治疗方法 |
CN111867576A (zh) * | 2017-11-22 | 2020-10-30 | 阿克塞斯全球科学有限责任公司 | 富含R-对映体的非外消旋β-羟基丁酸化合物和组合物及其使用方法 |
CN112334155A (zh) * | 2018-06-12 | 2021-02-05 | 柯特费布(9211-3133魁北克股份有限公司) | 新型生酮化合物、组合物、方法和其用途 |
CN112384211A (zh) * | 2018-06-04 | 2021-02-19 | 泰德尔塔有限公司 | 用于癌症恶病质的化合物 |
CN112996498A (zh) * | 2018-10-04 | 2021-06-18 | 泰德尔塔有限公司 | 在预防或治疗运动员过度训练中使用的化合物 |
CN113045416A (zh) * | 2021-03-23 | 2021-06-29 | 南京纽邦生物科技有限公司 | 一种(r)-3-羟基丁酰-(r)-3-羟基丁酯的制备方法 |
CN113329992A (zh) * | 2019-01-17 | 2021-08-31 | Ioi油脂化学品有限责任公司 | 基于多元醇的羟基羧酸酯的生产方法 |
CN113840538A (zh) * | 2019-05-21 | 2021-12-24 | 雀巢产品有限公司 | 膳食丁酸酯 |
CN114008015A (zh) * | 2019-06-12 | 2022-02-01 | Ioi油脂化学品有限责任公司 | 羟基羧酸多元醇酯、特别是聚甘油酯的制备方法 |
US11690817B2 (en) | 2017-11-22 | 2023-07-04 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
US11786499B2 (en) | 2017-11-22 | 2023-10-17 | Axcess Global Sciences, Llc | Ketone body esters of S-beta-hydroxybutyrate and/or S-1,3-butanediol for modifying metabolic function |
US11793778B2 (en) | 2018-04-18 | 2023-10-24 | Axcess Global Sciences, Llc | Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate |
US11806324B2 (en) | 2018-04-18 | 2023-11-07 | Axcess Global Sciences, Llc | Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies |
US11896565B2 (en) | 2016-03-11 | 2024-02-13 | Axcess Global Sciences, Llc | Beta-hydroxybutyrate mixed salt compositions and methods of use |
US11944598B2 (en) | 2017-12-19 | 2024-04-02 | Axcess Global Sciences, Llc | Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer |
US11950616B2 (en) | 2019-06-21 | 2024-04-09 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
US11969430B1 (en) | 2023-03-10 | 2024-04-30 | Axcess Global Sciences, Llc | Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance |
US12037317B2 (en) | 2018-01-25 | 2024-07-16 | Buck Institute For Research On Aging | Synthesis of 3-hydroxybutyryl 3-hydroxybutyrate and related compounds |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1648952T3 (en) | 2003-06-03 | 2018-05-28 | The Us Gov As Represented By The Department Of Health And Human Services | Dietary supplements and therapeutic compositions comprising (R) -3-hydroxybutyrate derivatives |
TR201908522T4 (tr) | 2008-01-04 | 2019-07-22 | The Government Of The U S A As Represented By The Secretary Dept Of Health And Human Services | Kan lipidi düşürücü maddeler olarak keton gövdeleri ve keton gövde esterleri. |
US8642654B2 (en) | 2009-04-16 | 2014-02-04 | Isis Innovation Limited | Hydroxybutyrate ester and medical use thereof |
GB201002983D0 (en) * | 2010-02-22 | 2010-04-07 | Tdeltas Ltd | Nutritinal composition |
US8329938B2 (en) * | 2011-02-21 | 2012-12-11 | Eastman Chemical Company | Hydroxyalkanoic acid and hydroxyalkanoice acid oligomer esters of retinol |
GB201206192D0 (en) * | 2012-04-05 | 2012-05-23 | Tdeltas Ltd | Ketone bodies and ketone body esters and for maintaining or improving muscle power output |
EP3659595A1 (en) | 2012-11-05 | 2020-06-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Ketone bodies to protect tissues from damage by ionizing radiation |
GB201304467D0 (en) * | 2013-03-12 | 2013-04-24 | Tdeltas Ltd | Compound for use in protecting skin |
GB201314127D0 (en) * | 2013-08-07 | 2013-09-18 | Tdeltas Ltd | Ketone body and ketone body ester for reducing muscle breakdown |
EP3094321B1 (en) * | 2014-01-13 | 2019-05-01 | University Of South Florida | Methods of sustaining dietary ketosis and its effects on lipid profile |
US11173138B2 (en) * | 2016-04-19 | 2021-11-16 | Keto Patent Group, Inc. | Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans |
US11026929B2 (en) | 2016-04-19 | 2021-06-08 | Keto Patent Group, Inc. | Administration of berberine metabolites |
SG11201810765PA (en) | 2016-06-07 | 2018-12-28 | The J David Gladstone Inst | Medium chain fatty acid esters of beta-hydroxybutyrate and butanediol and compositions and methods for using same |
US20180057846A1 (en) | 2016-08-30 | 2018-03-01 | KetoneAid Inc. | Partially buffered free acid and/or ketone blend for rapid onset ketosis and metabolic therapy |
GB201710229D0 (en) * | 2017-06-27 | 2017-08-09 | Tdeltas Ltd | Compounds for new use |
US11760963B2 (en) | 2017-08-23 | 2023-09-19 | KetoneAid Inc. | Ketogenic beer and alcoholic beverage mixture containing non-racemic ethyl 3-hydroxybutyrate and/or 1,3 butanediol |
GB2572185A (en) * | 2018-03-21 | 2019-09-25 | Chain Biotechnology Ltd | Pharmaceutical compositions |
JP7515407B2 (ja) * | 2018-06-21 | 2024-07-12 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | ニコチンアミドアデニンジヌクレオチド(nad+)前駆体及び少なくとも1種のケトン又はケトン前駆体を使用する組成物及び方法 |
MX2021013528A (es) | 2019-05-10 | 2021-12-10 | Ketoswiss Ag | Cuerpos cetonicos encerrados en microesferas. |
WO2020249198A1 (de) * | 2019-06-12 | 2020-12-17 | Ioi Oleo Gmbh | Verfahren zur herstellung von polyolbasierten estern von acylverkappten 3-hydroxycarbonsäuren |
WO2021195477A1 (en) * | 2020-03-27 | 2021-09-30 | Ketoneaid, Inc. | Ketone ester as a therapeutic treatment of covid-19, long covid, and related viral infections |
US20230174454A1 (en) * | 2020-05-12 | 2023-06-08 | Genomatica, Inc. | Process of synthesizing and purifying (3r)-hydroxybutyl (3r)-hydroxybutanoate |
BR112023000686A2 (pt) * | 2020-07-13 | 2023-02-07 | Ioi Oleo Gmbh | Processo para a produção de ésteres de poliglicerol de ácidos policarboxílicos esterificados com oxobutanol |
WO2023283654A1 (en) * | 2021-07-09 | 2023-01-12 | Georgia State University Research Foundation, Inc. | The use of beta-hydroxybutyrates for the treatment or prevention of aneurysms and dissections |
KR20240037239A (ko) | 2021-07-17 | 2024-03-21 | 케토스위스 아게 | 케톤체 또는 케톤 생성 화합물과 진통제 또는 항산화제의 조합 |
IT202100020441A1 (it) | 2021-07-30 | 2023-01-30 | Unichem Estense S R L | Miscela di un mono-estere e un di-estere, in cui detti mono-estere e di-estere sono esteri dell’acido (R)-3-idrossibutanoico con un polialcol, processo per la preparazione della miscela e relativi usi medici |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1524611A (en) * | 1975-01-07 | 1978-09-13 | Basf Ag | 1,3-butanediol mono - (3' -hydroxybutyrates) and process for their manufacture |
US5112865A (en) * | 1987-11-19 | 1992-05-12 | Solvay & Cie (Societe Anonyme) | Pharmaceutical compositions containing a derivative of 3-hydroxybutanoic acid chosen from oligomers of this acid and esters of this acid or of these oligomers with 1,3-butanediol |
WO2004108740A2 (en) * | 2003-06-03 | 2004-12-16 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Nutritional supplements and therapeutic compositions comprising (r)-3-hydroxybutyrate derivatives |
WO2007063037A2 (de) * | 2005-11-29 | 2007-06-07 | Basf Se | Verfahren zur um- oder veresterung von seitenketten in polymeren |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0755158B2 (ja) * | 1986-10-30 | 1995-06-14 | チッソ株式会社 | 光学活性エステルの製造法 |
JP4598203B2 (ja) * | 1995-12-01 | 2010-12-15 | ビーティージー・インターナショナル・リミテッド | 脳機能改善剤 |
EP1641444B1 (en) | 2003-06-02 | 2016-03-23 | Isis Innovation Limited | Treatment of muscle fatigue |
US8452351B2 (en) * | 2008-06-02 | 2013-05-28 | Qualcomm Incorporated | Methods and apparatus for saving battery power in mobile stations |
-
2009
- 2009-04-16 WO PCT/US2009/040766 patent/WO2010021766A1/en active Application Filing
- 2009-04-16 ES ES17176132T patent/ES2907630T3/es active Active
- 2009-04-16 PL PL17176132T patent/PL3296284T3/pl unknown
- 2009-04-16 EP EP21211530.7A patent/EP4011374A1/en active Pending
- 2009-04-16 ES ES09789596.5T patent/ES2655367T3/es active Active
- 2009-04-16 EP EP09789596.5A patent/EP2328858B1/en active Active
- 2009-04-16 DK DK09789596.5T patent/DK2328858T3/en active
- 2009-04-16 NO NO09789596A patent/NO2328858T3/no unknown
- 2009-04-16 AU AU2009283171A patent/AU2009283171B2/en active Active
- 2009-04-16 PL PL09789596T patent/PL2328858T3/pl unknown
- 2009-04-16 CA CA2734720A patent/CA2734720C/en active Active
- 2009-04-16 CN CN200980136723.1A patent/CN102164884B/zh active Active
- 2009-04-16 DK DK17176132.3T patent/DK3296284T3/da active
- 2009-04-16 EP EP17176132.3A patent/EP3296284B1/en active Active
- 2009-04-16 JP JP2011523833A patent/JP5773870B2/ja active Active
-
2012
- 2012-01-05 HK HK12100075.4A patent/HK1159604A1/zh unknown
-
2014
- 2014-11-28 JP JP2014241939A patent/JP6092836B2/ja active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1524611A (en) * | 1975-01-07 | 1978-09-13 | Basf Ag | 1,3-butanediol mono - (3' -hydroxybutyrates) and process for their manufacture |
US5112865A (en) * | 1987-11-19 | 1992-05-12 | Solvay & Cie (Societe Anonyme) | Pharmaceutical compositions containing a derivative of 3-hydroxybutanoic acid chosen from oligomers of this acid and esters of this acid or of these oligomers with 1,3-butanediol |
WO2004108740A2 (en) * | 2003-06-03 | 2004-12-16 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Nutritional supplements and therapeutic compositions comprising (r)-3-hydroxybutyrate derivatives |
WO2007063037A2 (de) * | 2005-11-29 | 2007-06-07 | Basf Se | Verfahren zur um- oder veresterung von seitenketten in polymeren |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105246870A (zh) * | 2013-03-14 | 2016-01-13 | 伊希斯创新有限公司 | (r)-3-羟基丁酸(r)-3-羟基丁酯的制备方法 |
CN103860533A (zh) * | 2014-02-12 | 2014-06-18 | 新乡医学院 | β羟基丁酸在治疗帕金森病中的应用 |
CN106456686A (zh) * | 2014-03-19 | 2017-02-22 | 斯坦陵布什大学 | 用于治疗或增强肌肉组织的方法 |
US11896565B2 (en) | 2016-03-11 | 2024-02-13 | Axcess Global Sciences, Llc | Beta-hydroxybutyrate mixed salt compositions and methods of use |
CN110248652B (zh) * | 2016-12-23 | 2023-05-26 | 鲁汶大学 | 3-羟基丁酸单独或组合用于治疗重症监护治疗 |
CN110248652A (zh) * | 2016-12-23 | 2019-09-17 | 鲁汶大学 | 3-羟基丁酸单独或组合用于治疗重症监护治疗 |
CN111050764A (zh) * | 2017-07-21 | 2020-04-21 | 巴克老年研究所 | β-羟基丁酸酯和丁二醇的S对映异构体及其使用方法 |
CN111132674A (zh) * | 2017-09-27 | 2020-05-08 | 泰德尔塔有限公司 | 治疗方法 |
US11648228B2 (en) | 2017-09-27 | 2023-05-16 | Tdeltas Limited | Method of treatment |
CN111867576A (zh) * | 2017-11-22 | 2020-10-30 | 阿克塞斯全球科学有限责任公司 | 富含R-对映体的非外消旋β-羟基丁酸化合物和组合物及其使用方法 |
US11786499B2 (en) | 2017-11-22 | 2023-10-17 | Axcess Global Sciences, Llc | Ketone body esters of S-beta-hydroxybutyrate and/or S-1,3-butanediol for modifying metabolic function |
US11690817B2 (en) | 2017-11-22 | 2023-07-04 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
US11944598B2 (en) | 2017-12-19 | 2024-04-02 | Axcess Global Sciences, Llc | Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer |
US12037317B2 (en) | 2018-01-25 | 2024-07-16 | Buck Institute For Research On Aging | Synthesis of 3-hydroxybutyryl 3-hydroxybutyrate and related compounds |
US11806324B2 (en) | 2018-04-18 | 2023-11-07 | Axcess Global Sciences, Llc | Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies |
US11793778B2 (en) | 2018-04-18 | 2023-10-24 | Axcess Global Sciences, Llc | Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate |
CN112384211A (zh) * | 2018-06-04 | 2021-02-19 | 泰德尔塔有限公司 | 用于癌症恶病质的化合物 |
CN112334155A (zh) * | 2018-06-12 | 2021-02-05 | 柯特费布(9211-3133魁北克股份有限公司) | 新型生酮化合物、组合物、方法和其用途 |
CN112996498A (zh) * | 2018-10-04 | 2021-06-18 | 泰德尔塔有限公司 | 在预防或治疗运动员过度训练中使用的化合物 |
CN113329992A (zh) * | 2019-01-17 | 2021-08-31 | Ioi油脂化学品有限责任公司 | 基于多元醇的羟基羧酸酯的生产方法 |
CN113329992B (zh) * | 2019-01-17 | 2024-04-30 | 凯托利皮克斯治疗有限责任公司 | 基于多元醇的羟基羧酸酯的生产方法 |
CN109700021A (zh) * | 2019-03-04 | 2019-05-03 | 清华大学 | 3-羟基丁酸及其衍生物在制备预防和治疗肥胖及肥胖相关疾病的产品中的应用 |
CN113840538A (zh) * | 2019-05-21 | 2021-12-24 | 雀巢产品有限公司 | 膳食丁酸酯 |
CN114008015A (zh) * | 2019-06-12 | 2022-02-01 | Ioi油脂化学品有限责任公司 | 羟基羧酸多元醇酯、特别是聚甘油酯的制备方法 |
CN114008015B (zh) * | 2019-06-12 | 2024-02-20 | 凯托利皮克斯治疗有限责任公司 | 羟基羧酸多元醇酯、特别是聚甘油酯的制备方法 |
US11950616B2 (en) | 2019-06-21 | 2024-04-09 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
CN113045416A (zh) * | 2021-03-23 | 2021-06-29 | 南京纽邦生物科技有限公司 | 一种(r)-3-羟基丁酰-(r)-3-羟基丁酯的制备方法 |
CN113045416B (zh) * | 2021-03-23 | 2023-08-18 | 南京纽邦生物科技有限公司 | 一种(r)-3-羟基丁酰-(r)-3-羟基丁酯的制备方法 |
US11969430B1 (en) | 2023-03-10 | 2024-04-30 | Axcess Global Sciences, Llc | Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance |
Also Published As
Publication number | Publication date |
---|---|
EP2328858A1 (en) | 2011-06-08 |
DK3296284T3 (da) | 2022-02-28 |
JP2015057427A (ja) | 2015-03-26 |
ES2655367T3 (es) | 2018-02-19 |
CA2734720C (en) | 2017-07-18 |
EP3296284B1 (en) | 2021-12-01 |
ES2907630T3 (es) | 2022-04-25 |
EP3296284A1 (en) | 2018-03-21 |
JP2012500264A (ja) | 2012-01-05 |
CA2734720A1 (en) | 2010-02-25 |
PL2328858T3 (pl) | 2018-06-29 |
JP5773870B2 (ja) | 2015-09-02 |
HK1159604A1 (zh) | 2012-08-03 |
JP6092836B2 (ja) | 2017-03-08 |
AU2009283171B2 (en) | 2014-08-14 |
DK2328858T3 (en) | 2018-01-15 |
AU2009283171A1 (en) | 2010-02-25 |
EP2328858B1 (en) | 2017-10-11 |
EP4011374A1 (en) | 2022-06-15 |
PL3296284T3 (pl) | 2022-06-13 |
CN102164884B (zh) | 2015-03-11 |
NO2328858T3 (zh) | 2018-03-10 |
WO2010021766A1 (en) | 2010-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102164884B (zh) | 羟基丁酸酯及其医学用途 | |
US20190014798A1 (en) | Hydroxybutyrate ester and medical use thereof | |
JP5121308B2 (ja) | メタボリックシンドロームの予防、改善または治療組成物 | |
JP6335508B2 (ja) | 成長ホルモン分泌促進剤 | |
US20060247310A1 (en) | Body temperature elevating agents | |
JP2003261456A (ja) | 脳の老化予防剤 | |
EP2027864B1 (en) | Composition for improvement of lipid metabolism | |
WO2005027892A1 (ja) | インスリン初期分泌促進剤 | |
JP2007230987A (ja) | 抗肥満剤 | |
JP2006016330A (ja) | 脂肪燃焼促進剤 | |
KR20220118504A (ko) | 비만 억제용 조성물 | |
JP4560864B2 (ja) | 新規なカプサイシノイド様物質を含有する鎮痛剤、食品及び飼料 | |
JP2002114676A (ja) | 新規なカプサイシノイド様物質を含有する持久力向上用組成物 | |
JP2007161703A (ja) | 抗疲労作用化合物および持久力増強作用化合物及びそれを含有する飲食品 | |
JP2020029407A (ja) | 概日リズム変調及びそれに起因する症状の予防又は改善用の内服剤並びに飲食品組成物 | |
JP4714438B2 (ja) | 抗疲労剤およびそれを含む飲食品 | |
JP2022129479A (ja) | 肝機能向上剤および肝機能向上用経口組成物 | |
JP2003342172A (ja) | カプサイシノイド様物質を含有する糖尿病血糖値低下組成物およびカプサイシノイド様物質の糖尿病血糖値低下剤としての使用 | |
JP2012206996A (ja) | 経口用のtranslocatorprotein(Tspo)遺伝子発現抑制剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1159604 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1159604 Country of ref document: HK |
|
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: oxford Patentee after: University of Oxford science and Technology Innovation Co., Ltd. Patentee after: Gvmt of The USA. As Represented Address before: oxford Patentee before: Isis Innovation Ltd. Patentee before: Gvmt of The USA. As Represented |